Figure 1.
Schematic illustration of the mechanism of nivolumab as IgG4 PD-1 immune checkpoint inhibitor antibody. Notes: Nivolumab prevents the binding of PD-1 to its ligands PD-L1 and PD-L2. This binding releases PD-1 pathway mediated immune responses against tumor cells. Abbreviations: IgG4, immunoglobulin G4; PD-1, programmed death-1; PD-L1, programmed death ligand-1; PD-L2, programmed death ligand-2.
